News tagged with bevacizumab
Related topics: patients , breast cancer , lung cancer , chemotherapy , ovarian cancer
Bevacizumab doesn't up overall survival in prostate cancer
(HealthDay) -- For men with metastatic castration-resistant prostate cancer (mCRPC), the addition of bevacizumab (B) to docetaxel plus prednisone (DP) is not associated with improved overall survival (OS), ...
Cancer
Mar 27, 2012 |
not rated yet |
0
Bevacizumab active in HIV-linked Kaposi's sarcoma
(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of ...
Cancer
Mar 20, 2012 |
not rated yet |
0
Study examines use of bevacizumab among patients with hereditary blood vessel disorder
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received ...
Diseases, Conditions, Syndromes
Mar 06, 2012 |
not rated yet |
0
CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness
Researchers at Virginia Commonwealth University Medical Center's VCU Massey Cancer Center and Harold F. Young Neurosurgical Center (Richmond, VA) and Old Dominion University (Norfolk, VA) have discovered that suppression ...
Neuroscience
Feb 07, 2012 |
not rated yet |
0
Avastin, Sutent increase breast cancer stem cells, study shows
Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't ...
Cancer
Jan 25, 2012 |
5 / 5 (1) |
1
|
Targeted therapy extends progression-free survival of patients with advanced ovarian cancer
Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic ...
Cancer
Dec 28, 2011 |
not rated yet |
0
|
Spread of nasopharyngeal carcinoma is reduced by bevacizumab, according to phase 2 trial results
The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.
Cancer
Dec 16, 2011 |
not rated yet |
0
Addition of bevacizumab to conventional therapy improved progression-free survival in HER2-positive breast cancer
Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from ...
Cancer
Dec 08, 2011 |
not rated yet |
0
Scientists find link between immune system suppression, blood vessel formation in tumors
Targeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin (bevacizumab), have slowed cancer growth in some patients. However, they have not produced the dramatic responses ...
Cancer
Jul 13, 2011 |
not rated yet |
0
|
Ovarian cancer outcomes may improve with 'dose-dense' chemotherapy
Dose-dense chemotherapy has shown promise in smaller clinical trials, and now is being investigated in a multi-center, phase III study in which nearly 700 women will participate. Earlier phase II trials pointed to anti-cancer ...
Cancer
Jun 30, 2011 |
not rated yet |
0
Blood proteins may identify vulnerability of pancreatic cancers to avastin
(Medical Xpress) -- Tiny tumor proteins circulating in blood may be used to identify which pancreatic cancer patients would benefit from the drug Avastin, researchers at Duke University Medical Center have found.
Cancer
Jun 07, 2011 |
not rated yet |
0
New drug combination slows tumor growth for recurrent ovarian cancer
Bevacizumab (Avastin) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by ...
Cancer
Jun 06, 2011 |
not rated yet |
0
Antifungal drug delays need for chemo in advanced prostate cancer
The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease. Details of the finding, from a clinical ...
Cancer
Jun 02, 2011 |
not rated yet |
0
Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox ...
Cancer
Jun 01, 2011 |
not rated yet |
0
